Today: 11 April 2026
Subscribe
Browse Category

Pharmaceuticals 17 October 2025 - 30 October 2025

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock on Fire: GLP-1 Bonanza, Big Earnings & AI Pivot Drive Rally

Eli Lilly reported Q3 2025 revenue of $17.60 billion, up 54% year-over-year, and raised full-year EPS guidance to $23.00–23.70. Shares closed at $813.53 on Oct. 29, down 2% over the week after hitting highs above $850 earlier in the month. The FDA approved Inluriyo for metastatic breast cancer, and the EU cleared Kisunla for early Alzheimer’s. Wall Street’s average 12-month price target stands near $939.
30 October 2025
···
Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics shares jumped nearly 50% to $1.80 intraday on October 29, 2025, after announcing a manufacturing partnership with Cellipont Bioservices to advance its ovarian cancer cell therapy, ERNA-101, toward clinical trials. Trading volume surged. Despite the rally, ERNA stock remains down about 58% in 2025 and 89% year-on-year after previous setbacks and a reverse stock split.
29 October 2025
··
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Over 62,000 pharmaceutical professionals from more than 170 countries are attending CPHI Frankfurt 2025, where executives are meeting to address global supply chain, regulation, and innovation challenges. Eli Lilly’s GLP-1 drugs generated $6.1 billion in Q1 2025, overtaking Novo Nordisk in the U.S. weight-loss drug market. Pharma giants are investing heavily as the global obesity treatment market is projected to reach $100 billion by 2030.
28 October 2025
····
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer (PFE) Stock Rebounds on Trump Drug Deal & Obesity Gamble – Can the Rally Last?

Pfizer shares traded near $24.76 on Oct. 24, up about 9% from their 52-week low but still down for the year. The stock jumped over 6% in late September after Pfizer reached a deal with the Trump administration to cut Medicaid drug prices, easing regulatory risk. Pfizer reports Q3 results Nov. 4, with analysts expecting lower earnings due to falling COVID product sales.
27 October 2025
··
Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis will acquire Avidity Biosciences for $12 billion in cash, offering $72 per share—a 46% premium over Avidity’s last close. Avidity’s stock, which ended Friday at $49.15, is expected to jump sharply when markets open. Novartis is targeting Avidity’s RNA therapies for rare muscle diseases, including a lead drug nearing FDA submission. The deal was announced Sunday, Oct. 26, 2025.
26 October 2025
····
Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

RVPH shares closed at $0.57 on Oct 24 after a volatile month, swinging between $0.26 and $0.84. The stock surged 28% on Oct 23 following recent Phase 3 trial results for brilaroxazine and news of an upcoming FDA meeting. Reviva raised about $19 million this year to fund its CNS pipeline. Analyst targets average $6.25, implying a potential 1,000% upside.
24 October 2025
···
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie (ABBV) Stock Up 28% YTD as New Drug Wins and Analyst Upgrades Fuel Optimism

AbbVie shares trade near $229, up 28% year-to-date and outperforming the S&P 500 healthcare index. The stock hit a record high in late September after a patent settlement extended U.S. exclusivity for Rinvoq until 2037. AbbVie announced a $2.7 billion R&D write-off in October, cutting profit guidance. FDA expanded Rinvoq’s use Oct. 13; a recent trial showed Rinvoq outperformed Humira in rheumatoid arthritis.
23 October 2025
·
Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

Scienture Holdings (NASDAQ: SCNX) jumped up to 45% in pre-market trading on Oct. 23, 2025, after announcing its first commercial sales of Arbli, the only FDA-approved ready-to-use liquid losartan. Trading volume surged to 77 million shares, far above its 4 million average. Despite the spike, SCNX remains down over 90% for the year. The company recently eliminated all debt by converting debentures to equity.
23 October 2025
··
Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Alkermes will acquire Avadel for $18.50 per share in cash, plus a $1.50 contingent payout, valuing the deal at about $2.1 billion. Avadel’s LUMRYZ sales are projected at $265–$275 million in 2025, with 3,100 patients on therapy. AVDL shares surged to near a 52-week high after the Jazz settlement and Alkermes news. Halper Sadeh LLC is investigating whether the offer undervalues Avadel.
22 October 2025
·····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk shares closed at $54.78 on Oct. 21, down nearly 50% in 2025 and wiping out about $70 billion in market value. The Novo Nordisk Foundation forced a board overhaul, with chair Helge Lund and six directors to be replaced. Novo announced deals to buy Akero for up to $5.2 billion and license Omeros’ OMS906 for up to $2.1 billion. U.S. price pressure and Eli Lilly’s competition have weighed on investor sentiment.
22 October 2025
··
Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Minerva Neurosciences shares jumped over 150% on October 21, 2025, after announcing a private placement to raise up to $200 million led by Vivo Capital. The cash will fund a Phase 3 trial and FDA resubmission for its schizophrenia drug roluperidone. Trading volume surged to 39.5 million shares, and the stock hit a new 52-week high near $6.80. Market cap rose from under $20 million to about $48 million.
21 October 2025
··
iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

iBio (NASDAQ: IBIO) traded at $0.89 midday October 21, down 63% year-to-date from $2.45 in January. Shares jumped over 20% last week after bullish “Outperform” ratings from Oppenheimer and Leerink Partners, with price targets of $5.00 and $2.00. The company reported positive preclinical results for its obesity drug IBIO-610 and raised $50 million in a recent offering. Market cap stands near $18 million.
21 October 2025
·
SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

Spero shares closed at $2.29 on Oct. 20, 2025, up 3.6%, after reporting Phase 3 trial results showing oral tebipenem HBr matched IV imipenem in overall success (58.5% vs 60.2%) at IDWeek. The stock has surged over 120% year-to-date, trading between $0.51 and $3.22. GSK plans an FDA submission in Q4. Analyst 12-month targets average $5, but ratings remain mixed following a recent Zacks downgrade.
21 October 2025
···
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharma Stock Soars 16% on AI Buzz and Big Pharma Deals – Can RXRX Keep Climbing?

Recursion Pharmaceuticals shares jumped over 16% to $6.80 intraday on Oct. 20, capping a volatile month that saw a 44% gain and heavy trading volume. CEO Chris Gibson sold 100,000 shares on Oct. 10 for about $604,000, drawing analyst scrutiny. The company reported a Q2 net loss of $171.9 million on $19.2 million revenue. Recursion recently acquired Exscientia in a $630 million all-stock deal.
20 October 2025
··
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer shares surged 15% from $23.6 to $27.2 after announcing a Medicaid pricing deal with the Trump administration and agreeing to buy obesity drug developer Metsera for up to $7.3 billion. Q2 revenue rose 10% to $14.7 billion, beating estimates. Pfizer trimmed its dividend but still yields 6–7%. Analysts raised price targets to $29–30, citing the pricing pact and new drug prospects.
19 October 2025
·
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics shares surged over 150% on Oct. 17, 2025, after announcing a collaboration and license deal with Chugai Pharmaceutical worth up to $1.085 billion. The company also raised $60.3 million in PIPE financing, stating it now has funding into 2028. Trading volume spiked to 70 million shares, up from a 300,000 average. Analyst opinions remain split on the stock’s outlook.
18 October 2025
···
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Gilead Sciences stock jumped over 4% on Oct. 17, 2025, closing at $122.81 and hitting a new 52-week high. The surge follows a patent settlement extending exclusivity for Biktarvy until 2036 and FDA approval of Yeztugo, a new HIV prevention shot. Gilead’s market cap stands near $150 billion after a 47% year-to-date gain. Analysts remain bullish but note concerns over U.S. drug pricing pressures.
18 October 2025
···
1 … 34 35 36 37 38

Stock Market Today

  • Top 5 Singapore Next 50 Stocks Outperform Blue Chips in Q1 2026
    April 11, 2026, 12:17 AM EDT. In Q1 2026, amid market volatility spurred by geopolitical tensions and rising oil prices, five Singapore Next 50 stocks outpaced blue chips with substantial gains. Frencken Group led with a 47.8% total return, driven by confidence in semiconductor recovery and expected capacity expansions in the US, Singapore, and Malaysia. The company reported better-than-expected FY2025 margins and growth in semiconductor and industrial automation divisions, despite a revenue dip in analytical life sciences. These outperformers highlight resilient pockets within Singapore equities, offering investors diversification beyond traditional blue chips during a turbulent first quarter.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 12:19 AM EDT Top 5 Singapore Next 50 Stocks Outperform Blue Chips in Q1 2026 April 11, 2026, 12:17 AM EDT. In Q1 2026, amid market volatility spurred by geopolitical tensions and rising oil prices, five Singapore Next 50 stocks outpaced blue chips with substantial gains. Frencken Group led with a 47.8% total return, driven by confidence in semiconductor recovery and expected capacity expansions in the US, Singapore, and Malaysia. The company reported better-than-expected FY2025 margins and growth in semiconductor and industrial automation divisions, despite a revenue dip
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop